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Abstract: The in-vitro activity of ofloxacin, lomefloxacin, ciprifloxacin, fleroxacin, DR-335, and 
PD-127391 which are all members of the fluoroquinolones and other unrelated (classical) 
antimicrobials that include, amoxycillin, sulphamethoxazole, trimethoprim, tetracycline and 
chloramphenicol have been compared against Salmonella typhi, campylobacter jejuni, Yersinia 
enterocolitica, Vibrio cholerae, Aeromonas hydrophila, and Vibrio parahaemolyticus.  Minimum 
inhibitory concentrations (MICs) of the antimicrobial agents examined were determined.  All 
members of the fluoroquinolones were highly active against all insolates examined and inhibited 
them at a concentration of <1mg/L. By contrast, many of the isolates examined were resistant to one 
or more of the classical antimicrobial agents.  These results showed a potential clinical role for all 
the fluoroquinolone compounds tested in the treatment or prophylaxis of bacterial enteric infections 
where antimicrobial intervention is indicated.[Ethiop. J. Health Dev. 1998;12(2)111:116]  
  
Introduction  
On a global scale, diarrhoeal diseases contribute to the greatest single cause of morbidity and 
mortality, far exceeding that from heart disease, cancer, or strokes in many parts of the world (1).  
Severe diarrhoeal diseases are among the most prevalent cause of infant and child-hood mortality in 
developing countries (2).  In Ethiopia diarrhoeal diseases are also the leading cause of death 
particularly among children under five years of age (3).  The bacterial species most frequently 
isolated from patients suffering from enteric diseases are Shigella spp., Salmonella spp., Entro- 
pathogenic and Enterotoxigenic strains of Escherichia coli, Campylobacter jejuni, Vibrio cholerae, 
Vibrio parahaemolyticus, Yersinia entrocolitica, and Aeromonas hydophila (4).  
In the case of secretory diarrhoea, the oral rehydration solution (ORS) plays an important role and 
in life-severe diarrhoea cases these sugar electrolyte  solutions  alone will not be  adequate and 
should be given together with a drug that reduces intestinal hyper-secretion (5).  Although their use 
remains controversial, antimicrobial agents have been used therapeutically and prophylactically for 
the treatment and prevention of enteric diseases for many years.  But, in many countries of the world, 
especially in the developing ones, the uncontrolled availability and use of orally active compounds 
such as ampicillin, chloramphenicol and tetracycline have resulted in widespread resistance amongst 
bacterial enteric pathogens (6) leaving clinicians of the developing countries no choice but to depend 
on more expensive antibiotics. These prevailing conditions have urged researchers to search for new 
antimicrobial agents which could be safe and easy to administer, cost effective to use, and, most 
importantly, carry minimal risk of developing resistant strains.  Fluorinated 4-quinolones are the 
new synthetic, orally administered antimicrobial agents.  They  
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have a high antimicrobial activity against a wide range of pathogenic organisms and resistance to 
this group of compounds occurs at a very low frequency (7).  Recent studies have indicated the 
emergence of resistant Gram   
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Table 1*: Comparative MICs in mg/L of selected antimicrobial agents against  
Salmonella typhi (n=24)   
Antimicrobials  MIC50  MIC90  Range   
Amoxycillin  0.5  1  0.5  - >64  
Sulphamethoxazole  32  64  16  - >256  
Trimethoprim  0.12  0.25  0.6  - >64  
Tetracycline  1  4  1  - >64  
Chloramphenicol  4  8  4   -  32  
Ofloxacin  0.3  0.06  0.03  -  0.12  
Ciprofloxacin  ≤0.008  0.015  ≤0.008   - 0.015  
Lomifloxacin  0.12  0.25  0.06   - 0.25  
Fleroxacin  0.03  0.03  0.008   - 0.25  
DR-3355  0.015  0.015  0.008   - 0.12  
Temafloxacin  0.03  0.03  0.015   - 0.25  
PD-127391    0.008  0.008  0.004  - 0.015  
  
*MIC50 and MIC90 are minimum inhibitory concentrations of the drug required 
to inhibit 50% and 90% of the bacterial isolates, respectively  
  
positive and Gram-negative strains of pathogenic bacteria against the fluoroquinolones (8,9). 
However the emergence of resistance among enteric pathogens is low and mostly occurs in E. coli 
(10,11).  In this study an attempt is made to compare the in-vitro antimicrobial activity of these 




Organisms:- The bacterial isolates were obtained from clinical materials examined in the 
Department of Clinical Microbiology at the University College Hospital, London, supplemented 
with isolates from Southern Europe, Africa, the Middle East, South and South-East Asia and South 
America.  The number of isolates delt with were Salmonella typhi (24), Yersinia enterocolitica (9), 
Campylobacter jejuni (30), Vibrio cholerae (24), Vibrio parahaemolyticus (25) and Aeromonas 
hydrophia (24).  The control strains used were Staphylococcus aureus (NCTC 5671) and Escherichia 
coli (NCTC 10418).  
Antimicrobial compounds:- Antibiotic reference powders obtained from various suppliers were 
tested over 512-0.002 mg/L range of concentration as indicated by the   
  
manufacturers for each compound.  The compounds were: amoxycillin, sulpha-methoxazole and 
tetracycline (Sigma Chemical Ltd.), trimethoprim (Welcome Foundation Ltd.), chloramphenicol 
(BDH Chemical Ltd.), ofloxacin, floxacin, CGD Searles Ltd.), Ciprofloxacin, (Bayer UK Ltd.), 
temafloxacin, (Abbott Laboratories), fleroxacin (Roche), DR-3355 (Daiichi Seiyaku) PD-127391 
(Warner-Lambert).  
Determination of antimicrobial susceptibility:-  Minimum inhibitory concentrations (MICs) of the 
antimicrobial agents for the bacterial isolates examined were determined using an agar incorporation 
technique (12) in Muller-Hinton medium (Oxoid Ltd., England) supplemented with saponin-lysed 
horse blood to a final concentration of 5% v/v, where necessary.  The inoculum was approximately 
104-105 colony forming units (cfu) of each isolate, contained in 1µl Muller-Hinton broth, which was 
delivered to the surface of the agar plates using a multipoint inoculator (Denley-Tech Ltd.).  
Following inoculation, plates were incubated in air at 370c for 24 h, except for C. jejuni spp. which 
required microaerophilic condition with the addition of about 10% CO2.  MICs were determined as 
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the lowest concentration of the antimicrobials tested which completely inhibited surface visible 
growth of the inoculum.  
  
Table 2*: Comparative MICs in mg/L of selected antimicrobial agents against Vibrio cholerae (n=24)   
Antimicrobials  MIC50  MIC90           Range   
Amoxycillin  8  >64  4   -  >64  
Sulphamethoxazole  256  >256  2   -  >256  
Trimethoprim  0.5  >64  0.03   -  >64  
Tetracycline  0.5  64  0.5    -  64  
Chloramphenicol  1  1  0.5    -  1  
Ofloxacin  0.015  0.015  ≤0.008     - 0.015  
Ciprofloxacin  ≤0.008  ≤0.008  all at  ≤0.008    
Lomifloxacin  0.015  0.015  ≤0.008   - 0.015  
Fleroxacin  0.015  0.015  0.008   - 0.015  
DR-3355  0.008  0.008  0.004   - 0.03  
Temafloxacin  0.015  0.015  0.004   - 0.015  
PD-127391    0.004  0.008    ≤0.002  - 0.008 
  
*MIC50 and MIC90 are minimum inhibitory concentrations of the drug required to inhibit 50% 
and 90% of the bacterial isolates, respectively  
  
Result  
The concentration of five classical antibiotics and seven 4-quinolones compounds required to 
inhibit 50% (MIC50) as well as 90% (MIC90) for all strains of salmonella typhi, Vibrio cholerae, 
Vibrio parahaemolyticus, campylobacter jejuni, Aeromonas hydrophila and the range of inhibition 
concentration, including Yersinia enterocolitica, were calculated and these are shown in Tables 16.  
All isolates tested were sensitive to the 4-quinolone compounds while mostly remaining resistant to 
the classical antibiotics.  
  
Discussion  
The two major limitations that exist for available antibacterial agents in the treatment of bacterial 
diarrhoea are the development of antimicrobial resistance among enteric pathogens and failure to 
obtain a satisfactory in-vivo clinical response to therapy in certain enteric infections despite the 
invitro susceptibility of the pathogens to available drugs (13).  
As many studies indicated most of the enteric pathogens especially in developing countries, are 
increasingly becoming resistant   
Antimicrobials  MIC50  MIC90           Range   
Amoxycillin  64  >64  16  - >64  
Sulphamethoxazole  128  >256  8  - >256  
Trimethoprim  2  4  0.25  -  4  
Tetracycline  1  1  0.5  -  2  
Chloramphenicol  1  1  0.5  -  2  
Ofloxacin  0.25  0.25  ≤0.008   - 0.25  
Ciprofloxacin  0.06  0.12  ≤0.008   - 0.12  
Lomifloxacin  0.25  0.25  0.015   - 0.5  
Fleroxacin  0.12  0.25  0.008   - 0.25  
DR-3355  0.12  0.12  0.004   - 0.12  
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Table 3*: Comparative MICs in mg/L of selected antimicrobial agents against Vibrio parahaemolyticus 
=25)   
  
*MIC50 and MIC90 are minimum inhibitory concentrations of the drug required to inhibit 50% 
and 90% of the bacterial isolates, respectively  
  
Table 4*: Comparative MICs in mg/L of selected antimicrobial agents against Campylobacter jejuni (n=30)   
Antimicrobials  MIC50  MIC90           Range  
Amoxycillin  8  32  2         - >64  
Sulphamethoxazole  128  256  16       -  256  
Trimethoprim  >64  >64  all at   - >64  
Tetracycline  0.5  >64  0.25    -  >64  
Chloramphenicol  4  4  2         - >64  
Ofloxacin  0.25  0.5  0.12     - 1  
Ciprofloxacin  0.12  0.25  0.06     - 0.5  
Lomifloxacin  0.5  0.5  0.25     -1  
Fleroxacin  0.25  0.5  0.25      -1  
DR-3355  0.12  0.12  0.06      - 0.5  
Temafloxacin  0.06  0.06  0.03      - 0.12  
PD-127391    0.03  0.03  0.015    -0.12 
*MIC50 and MIC90 are minimum inhibitory concentrations of the drug required to inhibit 50% 
and 90% of the bacterial isolates, respectively  
  
to the commonly available antimicrobial chemotherapy (14,15). Similarly, in the present study 
isolates obtained from different parts of the world were resistant to one or more of the other unrelated 
(classical) antimicrobial agents.   Most  of  the  isolates show MIC90 > 64 and >512.  Few isolates 
such as Aeromonas hydrophila and Salmonella typhi were sensitive to most of the classical 
antibiotics. While Vibrio cholera was sensitive to only chloramphenicol, Vibrio parahaemolyticus 
was sensitive to trimethoprim, tetracycline and chloramphenicol with MIC90 from 4mg/L to 1mg/L.  
Aeromonas hydrophila is similar to Vibrio parahaemolyticus but with an even lower MIC90 for all 
the three drugs indicated.  It had MIC90 of 1mg/L.  Although some of the isolates appeared to be 
sensitive within the strain, there were quite a number of organisms which were resistant.  Therefore 
resistance was on an increase amongst enteric pathogens world wide.  
The emergence of antimicrobial resistance among prevalent enteropathogens and the failure of 
certain bacterial enteric infections to respond to unrelated antimicrobial chemotherapy make the 
development and testing of new drugs advisable.  Thus the following 4-quinolone compounds which 
Temafloxacin  0.25  0.25  0.03   - 0.5  
PD-127391    0.06  0.06  0.004   - 0.06 
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include ofloxacin, Ciprofloxacin, lomefloxacin, fleroxacin, DR-3355, temafloxacin, and PD-127391 
are some of these synthetically produced  new  quinolone  compounds.   The  
  
Table 5*: Comparative MICs in mg/L of selected antimicrobial agents against Aeromonas hydrophila 
(n=24)   
Antimicrobials  MIC50  MIC90           Range   
Amoxycillin  >64  >64  64            - >64   
Sulphamethoxazole  128  128  8                - 256   
Trimethoprim  1  1  0.25            - 2   
Tetracycline  0.5  1  0.5            - 32   
Chloramphenicol  1  1  0.5            - 64   
Ofloxacin  0.015  0.015  ≤0.008      - 0.12   
Ciprofloxacin  ≤0.008  ≤0.008  ≤0.008       - 0.12   
Lomifloxacin  0.015  0.03  0.015         - 1   
Fleroxacin  0.015  0.015  0.008         - 1   
DR-3355  0.008  0.008  0.004         - 0.5   
Temafloxacin  0.03  0.06  ≤0.008        - 0.5   
PD-127391    0.004  0.008  ≤0.002     -0.12 
  
*MIC50 and MIC90 are minimum inhibitory concentrations of the drug required to inhibit  
50% and 90% of the bacterial isolates, respectively  
  
4-quinolone group of compounds displayed very high potency of activity against all the isolates 
examined and inhibited them at a concentration of ≤1mg/L (Tables).  
   In the present study PD-127391 showed the highest activity compared with the other 4-quinolones 
tested together against the enteric pathogens.  The MIC90 of PD-127391 for Salmonella typhi, Vibrio 
cholerae and Aeromonas hydrophila was 0.008mg/L.  For Vibrio parahaemolyticus it was 0.06mg/L 
whereas Campylobacter jejuni showed high sensitivity compared with the other groups of 
4quinolones.  Its MIC90 was only 0.03mg/L.   
  
Table 6: Comparative MICs in mg/L of selected antimicrobial agents against Yersinia enterocolitica (n=9)   
Antimicrobials  MIC50  MIC90           Range  
Amoxycillin  -  -  1  -  >64  
Sulphamethoxazole  -  -  8  -  >512  
Trimethoprim  -  -  0.25   -  4  
Tetracycline  -  -  1  -  4  
Chloramphenicol  -  -  1  -  8  
Ofloxacin  -  -  ≤0.008  -  0.12  
Ciprofloxacin  -  -  ≤0.008  -  0.015  
Lomifloxacin  -  -  0.015  -  0.12  
Fleroxacin  -  -  0.03  -  0.12  
DR-3355  -  -  0.008  -  0.06  
Temafloxacin  -  -  0.004  -  0.06  
PD-127391    -  -  ≤0.002  -  0.015 
The report of other investigations also showed that this compound is one of the promising 
compounds with high activity against a wide range of organisms of medical importance (16).  The 
second most active compound against the enteric pathogens tested in our study was Ciprofloxacin. 
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The MIC90 of Ciprofloxacin for salmonella typhi, Vibrio cholerae, Aeromonas hydrophila and 
Vibrio parahaemolyticus was much lower than that for campylobacter jejuni (Table).  On the other 
hand all species of Yersinia enterocolitica were susceptible to all the 4-quinolone compounds.  The 
most active compound of all still remained PD-127391.  
The other members of 4-quinolone compounds investigated in this study were less active than 
PD-127391 and Ciprofloxacin.  When compared with the classical anti-microbial agents, however, 
they were still very active.  
From the results presented and other earlier studies (7,16) the new synthesized fluoroquinolones, 
which are now on the market and those which are still under experimental investigations, were found 
to be highly effective compounds against enteric pathogens in vitro in very low concentrations 
compared with the classical antimicrobial agents.  Thus this group of compounds has potential as 
alternative treatment in most countries of the world, particularly in the developing ones where the 
problem of resistance to the classical antimicrobial agents is becoming increasingly very high.  A 
similar study is suggested to see the effect of these antimicrobials against Ethiopian strains.  
Fluoroquinolones have little or no effect on the normal gut flora compared with those 
antimicrobial agents classically used to treat enteric pathogens (17).  This characteristic enhances 
the potential of this group of compounds in clinical practice.  However, a recent study has shown 
that fluoroquinolones were found to cause cartilage damage as well as arthropathy in young animals 
(18,19,20).  As a result of these findings fluoroquinolones are not advisable for use in pre-pubertal 
children and in pregnant or nursing women.  The fluoroquinolones which are undergoing clinical 
trails and those which are at various stages of experimental development must therefore be well 
evaluated before they are released for routine use in clinical practice for the treatment and prevention 
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